Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

enzalutamide

Known as: Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl- 
An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
BACKGROUND Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2018
Highly Cited
2018
BACKGROUND Men with nonmetastatic, castration‐resistant prostate cancer and a rapidly rising prostate‐specific antigen (PSA… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2014
Highly Cited
2014
BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
BACKGROUND The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2014
Highly Cited
2014
BACKGROUND Abiraterone, an androgen synthesis inhibitor, has been successfully used in the treatment of castration-resistant… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • table 3
Highly Cited
2013
Highly Cited
2013
Persistent androgen receptor (AR) transcriptional activity underlies resistance to AR-targeted therapy and progression to lethal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2013
Highly Cited
2013
UNLABELLED Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
2013
Highly Cited
2013
UNLABELLED Castration-resistant prostate cancer (CRPC) is the most aggressive, incurable form of prostate cancer. MDV3100… Expand
Highly Cited
2013
Highly Cited
2013
IntroductionThe androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a therapeutic target in… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
2012
Highly Cited
2012
BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3